	US 11,834,687 B1
	Chimeric endolysin polypeptide
Fritz Eichenseher, Baar (DE); Mathias Schmelcher, Baar (DE); and Christian Alexander Rohrig, Baar (DE)
Assigned to Micreos Pharmaceuticals AG, Baar (DE)
Filed by Micreos Pharmaceuticals AG, Baar (DE)
Filed on May 10, 2023, as Appl. No. 18/314,859.
Application 18/314,859 is a division of application No. PCT/EP2023/055392, filed on Mar. 3, 2023.
Claims priority of application No. 22160211.3 (EP), filed on Mar. 4, 2023.
Int. Cl. C12N 9/24 (2006.01); A61K 45/06 (2006.01); A61P 31/04 (2006.01); C12N 15/63 (2006.01)

CPC C12N 9/2402 (2013.01) [A61K 45/06 (2013.01); A61P 31/04 (2018.01); C12N 15/63 (2013.01)]

6 Claims

1. An endolysin polypeptide that has lytic activity for Staphylococcus aureus Staphylococcus delphini, Staphylococcus hyicus, Staphylococcus intermedius, Staphylococcus lutrae, Staphylococcus pseudintermedius, Staphylococcus schleiferi subsp. coagulans, or Staphylococcus simulans, said endolysin polypeptide comprising a polypeptide having an amino acid sequence that has at least 83% sequence identity with SEQ ID NO: 1.